INIS
usa
100%
cancer
83%
humans
66%
vaccines
64%
doses
42%
carcinomas
37%
patients
36%
comparative evaluations
34%
covid-19
33%
people
33%
males
33%
females
33%
breasts
33%
testing
33%
ovaries
33%
cost
33%
populations
33%
risks
22%
data
19%
surgery
12%
women
9%
levels
9%
mortality
8%
chemotherapy
8%
immunotherapy
8%
interventions
7%
age groups
7%
cardiovascular diseases
7%
carriers
7%
management
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
50%
COVID-19 Vaccine
33%
Severe Acute Respiratory Syndrome
33%
Human Papillomavirus
33%
Infection
33%
Endometrium Carcinoma
33%
Incidence
33%
Vaccine
31%
Chemotherapy
16%
Immunotherapy
16%
Endometrium Cancer
16%
Reinfection
13%
Neoplasm
8%
Disease
8%
Overall Survival
8%
Comorbidity
8%
SARS Coronavirus
6%
Keyphrases
High-risk Human Papillomavirus (HR-HPV)
33%
United States
33%
Human Papillomavirus Vaccine
20%
Revaccination
13%
Treatment Trends
8%
Rising Incidence
8%
Cancer Incidence
6%
SARS-CoV-2 Reinfection
6%
U.S. Cancer Statistics
6%
Incidence Rate
6%
Young Males
6%
Age Groups
6%
Early Effect
6%
Average Annual Incidence Rate
6%
Post-marketing Surveillance
6%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
6%
